Welcome to our dedicated page for Solventum Corporation SEC filings (Ticker: SOLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to untangle Solventum鈥檚 first stand-alone SEC reports? The company鈥檚 four-segment model鈥攕panning advanced wound dressings, AI-powered health IT, dental aligner tech, and critical filtration鈥攖urns each disclosure into a maze of clinical data, reimbursement nuances, and spin-off accounting details.
Stock Titan turns those 300-page documents into clear answers. Our AI produces plain-English summaries so Solventum SEC filings are explained simply. Need the latest Solventum quarterly earnings report 10-Q filing? It鈥檚 here with key wound-care margins highlighted. Curious about management鈥檚 confidence? Receive Solventum Form 4 insider transactions real-time alerts before markets react. When an unexpected recall hits, our feed delivers a Solventum 8-K material events explained brief in minutes.
Every filing type is covered and refreshed the moment it hits EDGAR:
- 10-K 鈥� full-year deep dive with segment revenue and R&D spend, now a Solventum annual report 10-K simplified by AI.
- 10-Q 鈥� quarter-over-quarter trends, cash-flow swings, and AI-driven Solventum earnings report filing analysis.
- 8-K 鈥� recalls, FDA clearances, and acquisitions decoded fast.
- Form 4 鈥� track Solventum executive stock transactions Form 4 with instant notifications.
- DEF 14A 鈥� your window into Solventum proxy statement executive compensation and governance policies.
Whether you monitor insider buying patterns, compare MedSurg growth to Dental Solutions, or need footnote-level spin-off tax details, Stock Titan鈥檚 AI-powered summaries, expert context, and real-time alerts keep you ahead鈥攏o medical dictionary required.
Solventum Corporation filed a Form S-3 prospectus dated August 13, 2025 to register for resale up to 34,369,190 shares of its common stock held by 3M Company. The selling shareholder will receive all proceeds from any sales; Solventum will not receive proceeds from this offering. The prospectus cites a last reported sale price of $72.09 per share on August 12, 2025 and states there were 173,387,798 shares outstanding as of July 31, 2025. The registration statement will be kept effective under a Registration Rights Agreement through August 13, 2027 or until all registered shares are sold.
The filing describes Solventum as a global healthcare company with a 70+ year history, spun off from 3M on April 1, 2024. Corporate features disclosed include authorized capital of 750,000,000 common shares and 50,000,000 preferred shares, one vote per common share, no preemptive rights, a classified board in effect until 2028, and indemnification and D&O insurance. The prospectus highlights material risk factors explicitly, including that future sales by 3M could adversely affect the market price, spin-off-related costs and tax risks, potential PFAS liabilities, supply chain and regulatory risks, and other operational and financial risks incorporated by reference into the filing.
Solventum disclosed unaudited pro forma condensed consolidated financial statements reflecting a previously announced Transaction with Thermo Fisher Scientific to sell Solventum's purification and filtration business, as amended to exclude the drinking water filtration business. The amended agreement reduces the expected cash consideration from approximately $4.10 billion to approximately $4.00 billion, with closing price subject to customary adjustments.
The pro forma balance sheet is presented as if the Transaction occurred on June 30, 2025 and pro forma income statements assume the Transaction occurred on January 1, 2024 for periods shown. The filing notes the pro forma statements are illustrative, prepared under Article 11 of Regulation S-X, and do not reflect certain items including the Company鈥檚 intended use of net proceeds or potential corporate overhead reallocations related to the divestiture. The pro forma statements are filed as Exhibit 99.1.
Solventum Corporation received a Schedule 13G disclosure from Independent Franchise Partners, LLP, a United Kingdom investment adviser, reporting beneficial ownership of 10,141,066 common shares, representing 5.86% of the outstanding class. The filing covers the issuer's common stock and identifies the reporting person as an IA (investment adviser).
The statement shows sole voting power over 10,011,852 shares and sole dispositive power over 10,141,066 shares, and includes a certification that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control. The disclosure notifies investors of a passive, material stake above the 5% reporting threshold.
Solventum has amended its transaction agreement with Thermo Fisher Scientific regarding the sale of its purification and filtration business. Key changes include:
- Excluding the drinking water filtration business from the sale
- Reducing purchase price from $4.10 billion to $4.00 billion
- Adding potential $75 million payment to Solventum upon future sale of water business or after 3 years
- Transaction still expected to close by end of 2025
Financial impact: The retention of water business will increase previously estimated annual EPS accretion beyond 15-20 cents, but reduce projected improvements in gross margin (was 200bps) and operating margin (was 100bps). Updated estimates will be provided during Q2 earnings call. Net proceeds will primarily be used for debt reduction. The amendment aims to decrease complexity and potentially accelerate closing timeline.
FAQ
What is the current stock price of Solventum Corporation (SOLV)?
What is the market cap of Solventum Corporation (SOLV)?
